Document Detail

Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.
MedLine Citation:
PMID:  8398335     Owner:  NLM     Status:  MEDLINE    
25 patients with residual or recurrent ovarian cancer were treated with the new platinum complex zeniplatin (CL 286,558) and 23 patients were evaluable for response. Responses were achieved in 4 patients, 1 complete and 3 partial remissions (16%). 7 patients had stable disease and 12 patients had tumour progression. At a median follow-up of 12 months, the median progression-free survival in responding patients was 11 months and overall survival 81%. The median overall survival of progressive patients amounted to 9 months, indicating the advanced stage of disease in most patients. Renal function was monitored by isotope clearance studies. There was no significant change in effective renal plasma flow (ERPF) or glomerular filtration rate (GFR) in 10 patients who completed six cycles of treatment. 1 patient with a marginal creatinine clearance at baseline suffered from sudden and severe renal failure during the first cycle. Zeniplatin may be active in relapsing, platinum-pretreated patients, and has no direct effects on renal function as measured by isotope clearance. Despite these findings, occasional nephrotoxicity may occur in patients with compromised kidney function, even with prophylactic hydration, and thus limit the application of this new analogue.
P H Willemse; J A Gietema; N H Mulder; E G de Vries; S Meijer; J Bouma; M Birkhofer; R B Rastogi; D T Sleijfer
Related Documents :
7742225 - The effect of triple therapy on rapidly progressive type of henoch-schönlein nephritis.
8251315 - Treatment of iga nephropathy in children: efficacy of alternate-day oral prednisone.
9720525 - Ureteroscopic evaluation and treatment of chronic unilateral hematuria.
18297315 - Prognostic factors in children with membranoproliferative glomerulonephritis type i.
8069425 - Blunt injury to the subclavian or axillary artery.
2330105 - The relationship of age to outcome in myasthenia gravis.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  29A     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1993  
Date Detail:
Created Date:  1993-11-01     Completed Date:  1993-11-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  359-62     Citation Subset:  IM    
Department of Medical Oncology, University Hospital Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  therapeutic use*
Blood Flow Velocity / drug effects
Carboplatin / adverse effects,  analogs & derivatives*,  therapeutic use
Glomerular Filtration Rate / drug effects
Kidney / blood supply
Kidney Diseases / chemically induced
Middle Aged
Ovarian Neoplasms / drug therapy*
Remission Induction
Vomiting / chemically induced
Reg. No./Substance:
0/Antineoplastic Agents; 111490-36-9/zeniplatin; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and...
Next Document:  Prognostic significance of Ki67 labelling in resected non small cell lung cancer.